{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:55:12Z","timestamp":1784138112847,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"\n \n \n Abstract: Background:<\/jats:italic>\n <\/jats:bold>\n <\/jats:underline>\n Atopic dermatitis (AD) is an immune system-mediated, complex skin disease. Additional treatment options are needed to provide a better and faster clinical response for patients with AD.\n <\/jats:p>\n \n \n \n Objective:<\/jats:italic>\n <\/jats:bold>\n <\/jats:underline>\n Investigate the difference in efficacy for the rapid relief from pruritus in adults with moderate-to-severe AD.\n <\/jats:p>\n \n \n \n Methods:<\/jats:italic>\n <\/jats:bold>\n <\/jats:underline>\n A 12-week prospective, cohort, observational, single-center study was conducted in adults with moderate-to-severe AD. Patients were assigned randomly (in a 1:1:1 ratio) to receive upadacitinib, abrocitinib, or dupilumab. Pruritus is a key symptom of AD, so the primary endpoint was a reduction in the weekly average worst pruritus Numerical Rating Scale (NRS) score by \u22653 points from baseline at week 4. In addition, we analyzed the response rate at each visit for 75% improvement in Eczema Area and Severity Index (EASI75) and validated Investigator's Global Assessment for Atopic Dermatitis 0\/1 (vIGA-AD 0\/1).\n <\/jats:p>\n \n \n \n Results:<\/jats:italic>\n <\/jats:bold>\n <\/jats:underline>\n Baseline characteristics was balanced among treatment groups, including measures of disease severity. After 4 weeks of treatment, there was a significant increase in the proportion of patients treated with Janus kinase (JAK) inhibitors who experienced a reduction of \u22653 points in the NRS score compared with those receiving dupilumab. After further treatment, JAK inhibitors resulted in a further reduction of NRS in patients, with a higher percentage of patients achieving EASI75 and vIGA 0\/1 (particularly upadacitinib). In addition, no additional serious adverse events were observed during the 12-week follow-up period.\n <\/jats:p>\n \n \n \n Conclusions:<\/jats:italic>\n <\/jats:bold>\n <\/jats:underline>\n JAK inhibitors could be considered as effective treatment options for patients with moderate-to-severe AD, particularly upadacitinib, which has shown the greatest efficacy in reducing itching with a favorable safety profile.\n <\/jats:p>","DOI":"10.1089\/derm.2023.0132","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T11:36:20Z","timestamp":1699270580000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-1467","authenticated-orcid":false,"given":"Dawei","family":"Huang","sequence":"first","affiliation":[{"name":"From the, Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China."},{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China."},{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China."},{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tan","sequence":"additional","affiliation":[{"name":"From the, Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China."},{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.039"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00643-4"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00548-6"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01638-3"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102002"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17351"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0383-4"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:07:12Z","timestamp":1777399632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1089\/derm.2023.0132"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0132","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}